Page last updated: 2024-09-03

gefitinib and su 1498

gefitinib has been researched along with su 1498 in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (su 1498)	Trials (su 1498)	Recent Studies (post-2010) (su 1498)
5,231	566	2,919	56	0	23

Protein Interaction Comparison

Protein	Taxonomy	gefitinib (IC50)	su 1498 (IC50)
Vascular endothelial growth factor receptor 2	Homo sapiens (human)		0.7

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M	1
Amin, DN; Bielenberg, DR; Heymach, JV; Klagsbrun, M; Lifshits, E	1

Other Studies

2 other study(ies) available for gefitinib and su 1498

Article	Year
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51 Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases	2007
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvascular research, 2008, Volume: 76, Issue:1 Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2	2008

Article

Year

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.

Microvascular research, 2008, Volume: 76, Issue:1

Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2

2008